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Internal fixation treatments 
for intertrochanteric fracture: 
a systematic review and meta-
analysis of randomized evidence
Jiajie Yu1, Chao Zhang2, Ling Li1,3, Joey S.W. Kwong1,3, Li Xue4, Xiantao Zeng5, Li Tang6, 
Youping Li1,3 & Xin Sun1,2,3
The relative effects of internal fixation strategies for intertrochanteric fracture after operation remain 
uncertain. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) 
to address this important issue. We searched PubMed, EMBASE and CENTRAL for RCTs that compared 
different internal fixation implants in patients with intertrochanteric fracture at 6-month follow-up or 
longer. We ultimately included 43 trials enrolling 6911 patients; most trials were small in sample sizes 
and events. Their risk of bias was generally unclear due to insufficient reporting. Because of these, no 
statistically significant differences were present from most of the comparisons across all the outcomes, 
and no definitive conclusions can be made. However, a number of trials compared two commonly 
used internal fixation strategies, gamma nail (GN) and sliding hip screw (SHS). There is good evidence 
suggesting that, compared to SHS, GN may increase the risk of cut out (OR = 1.87, 95% CI, 1.08 to 3.21), 
re-operation (OR = 1.61, 95% CI, 1.02 to 2.53), intra-operative (OR = 3.14, 95% CI, 1.34 to 7.35) and later 
fractures (OR = 3.67, 95% CI, 1.37 to 9.83). Future randomized trials or observational studies that are 
carefully designed and conducted are warranted to establish the effects of alternative internal fixation 
strategies for intertrochanteric fracture.
Hip fractures represent a common type of injuries; its number increases rapidly1. By 2050, the number of hip 
fractures is estimated to surpass 6.3 million2. The 1-year mortality for hip fractures range from 14% to 36%3. Hip 
fractures include femoral neck and intertrochanteric factures4; 20 to 30 percent of patients died in the first 12 
months after an intertrochanteric fracture, especially those elderly with limited activity5,6. Surgical treatment rep-
resents the optimal strategy for managing intertrochanteric fractures. It allows early rehabilitation and functional 
recovery, and reduces the risk of postoperative complications7.
Internal fixation is a most common surgical treatment for intertrochanteric fractures3, and intramedually 
(nails) and extramedually (screws or plates) fixations are two commonly used approaches8. The established ben-
efits of internal fixation treatments are immediate pain relief, rapid mobilization, accelerated rehabilitation and 
maintenance of independent living.
Several systematic reviews and meta-analysis have tested the effects of different internal fixation implants to 
provide insight into the options for treating intertrochanteric fractures from 2000 to 20129–13. However, the find-
ings in these studies are inconsistent and the diversity of devices used for intertrochanteric fractures had made it 
challenging for decision makers to identify the ideal treatment option. Meanwhile, the techniques and implants 
continue to be modified, which make the previous literature less relevant to current practice.
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Therefore, we conducted a systematic review and meta-analysis, aiming to offer a comprehensive assessment 
of alternative internal fixation treatments for intertrochanteric fractures. The protocol of this study was registered 
on the PROSPERO database (CRD42014008795).
Materials and Methods
Study selection. We included prospective, randomized controlled trials (RCTs) published in English if 
they enrolled participants diagnosed with intertrochanteric fractures; compared currently used internal fixation 
implants; followed up patients for more than 6 months; and reported any of our pre-defined outcome measures 
of interest.
The currently available internal fixations included gamma nail (GN), ACE nail, holland nail, proximal femoral 
nail (PFN), proximal femoral nail antirotation (PFNA), intramedullary hip screw (IMHS), sliding hip screws (SHS), 
dynamic condylar screw (DCS), locking compression plate (LCP), percutaneous compression plate (PCCP), Medoff 
sliding plate, Targon proximal femoral and less invasive stabilization system (LISS).
The pre-defined outcomes included functional measures (i.e. quality of life scores, function scores), adverse 
events (i.e. mortality, cut out, non-union, reoperation, intra-operative fracture, later fracture, wound infection and 
embolism), and procedure measures (i.e. operative time, blood loss and hospital stay).
We excluded studies if patients had subtrochanteric fractures, pathological fractures, or previous femoral 
fractures.
Data sources and searches. We searched PubMed, EMbase (via OVID) and the Cochrane Central Register 
of Controlled Trials (CENTRAL) from inception up to May, 2015 (Search strategy in appendix 1). We also searched 
ClinicalTrial.gov and the reference lists of included studies to identify additional eligible studies. To ensure com-
pleteness, we also cross referenced our search results with relevant published Cochrane systematic reviews of 
extracapsular hip fractures14.
Study procedures. We used standardized pilot-tested data extraction forms for the screening of the abstracts 
and full texts, assessment of risk of bias and collection of data. Pairs of reviewers (YJJ, LL) independently screened 
study report for eligibility, assessed risk of bias and collected data from each eligible study. Discrepancies were 
resolved through discussion.
Risk of bias assessment. We assessed the risk of bias of RCTs using a modified version of the Cochrane 
Collaboration’s tool15. The items included random sequence generation, allocation concealment, blinding of par-
ticipants, surgeons or outcome assessors, completeness of outcome data, and selective reporting. We included two 
additional items regarding “standardization of the operative procedures” and “surgeons’ experience clearly defined 
with operations” because the validity of findings from surgical RCTs depends largely on quality of operation and 
surgeons’ experience16.
Data extraction. We extracted the following data from each of the eligible studies: study characteristics 
(publish year, simple size, country, length of follow up), patient characteristics (gender, age, type of fracture); 
interventions (intramedullary and extramedullary treatments) and outcomes (quality of life scores, function scores, 
mortality, cut out, non-union, reoperation, operative fracture, later fracture, wound infection, embolism, operative 
time, blood loss and hospital stay)
Data analyses. In the analysis of quality of life data, we reported the data at the baseline, end of the follow 
up, and the change from the baseline. For functional score data, because of the scanty in the reporting of the base-
line data, we compared means at the end of follow up of those outcomes between treatment and control groups, 
assuming that the randomization has well achieved the balance of the baseline between groups. For each of the 
comparison, we pooled the quality of life data and the functional scores using weighted mean difference (MD) or 
standardized mean difference (SMD) if varying measures were used. In the analysis of the operation time, blood 
loss, and hospital stay, we treated each of the outcome measures as normally distributed, and pooled the mean 
differences for each of the comparison, and reported 95% confidence intervals. We also pooled, for each of the 
comparison, the trial data regarding adverse events.
In the meta-analyses, we applied the random-effects model using Mantel-Haenszel method. We examined het-
erogeneity by Cochran’s Q test and I2 statistic. Where possible, we conducted, for each meta-analysis, a pre-defined 
subgroup analysis by fracture types (stable fractures vs. unstable fractures by AO/OTA classification) to explore 
source of heterogeneity.
We performed sensitivity analyses by using alternative pooling methods (Peto method vs. Mantel-Haenszel 
method applicable to dichotomous data) and alterative statistical model (random vs. fixed effect). We performed 
the data analysis by the RevMan 5.3.
Results
Characteristics of included studies. The search yielded 3,397 potential relevant reports. After screening 
of titles and abstracts, 234 records were retrieved for judging final eligibility. We eventually included 43 RCTs 
involving 6911 patients (Fig. 1). These trials were conducted in 18 countries, of which 4 were international trials. 
The sample sizes ranged from 40 to 600, and the length of follow up from 6 to 40 months.
Among those trials, 52.4% (3625/6911) of the participants were female; the mean age ranged from 53.9 to 
84.3 years; 30 trials (69.8%) recruited both stable and unstable fractures (n = 5010), 12 trials explored the effects 
of devices on unstable patients (n = 1695), and 1 trial did not report the fracture type of participants (n = 206) 
(Table 1).
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Those 43 trials investigated 11 internal fixation treatments, including GN, ACE nail, holland nail, PFN, PFNA, 
IMHS, SHS, PCCP, Medoff sliding plate, Targon proximal femoral and LISS. The types of implants under assess-
ment varied considerably across studies; few studies tested a same comparison. The details of comparisons were 
presented in Table 1.
Among those 43 trials, 14 (32.5%) adequately generated random sequences; 9 (20.9%) adequately concealed 
allocation; none blinded patients and surgeons; 10 (21.7%) blinded outcome assessors; 28 (65.1%) reported more 
than 80% of patients with completed follow up; only 1 (2.2%) did not report their pre-defined outcomes; 7 trials 
(15.2%) explicitly stated that surgeons standardized their operations by manuals or guidelines; and 31 (67.4%) 
referred that surgeons were experienced with trial operations (appendix 2).
Effects on quality of life and functional measures. Quality of life scores (QoL scores). Four trials 
(n = 420) used EuroQol 5D (EQ-5D) and Short Form (36) Health Survey (SF-36) to measure the effects of inter-
nal fixation treatments on the quality of life17–20, all of which were small in sample sizes. Two studies provided 
the baseline and follow up date on quality of life17,19; compared to the baseline, the scores at the end of follow up 
decreased. In the comparison of the data at the end of follow up, GN group had a significant higher score than 
SHS group in one trial reporting EQ-5D (MD: 0.12, 95%CI 0.02 to 0.22); in another small trial, no significant 
difference in the SF-36 was present between GN and PFNA (Table 2). The other two studies neither provided the 
data regarding standard deviation nor baseline.
Functional scores. Sixteen trials (n = 1467), consisting of 10 comparisons, reported functional status by 6 scores, 
including Parker-and-Palmer mobility score, Harris hip score, Jensen social-function score, Merle d’aubigne hip 
score, Geriatric hip fracture recovery scores, and Barthei index17,19,21–32. Ten studies provided the baseline and 
follow up date, all of which showed that functional scores decreased at the end of follow up17,22–24,26,27,29,30,33,34.
Eight trials compared GN versus 3 other devices (SHS, ACE nail and PFNA); 4 trials compared SHS versus 
other 4 devices (IMHS, PFN, PFNA, Medoff sliding plate); and 4 trials compared PFNA versus other 3 implants 
(LISS, Targon PF, PCCP) (appendix Fig. 1).
The comparison of means at the end of follow up showed that patients at GN group had a higher score com-
pared to those at SHS group (SMD: 0.23, 95%CI 0.01 to 0.46, I2 = 22%), but had a lower score than PFNA group 
Figure 1. Flaw diagram of study selection based on the eligibility criteria . We initially searched 8937 reports 
and 3397 potential relevant reports were included in title and abstract screening after duplication (n = 5540). 
After screening of titles and abstracts, 234 records were retrieved for judging final eligibility. We eventually 
included 43 RCTs after full text reviewing.
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fracture Follow up 
(month)E C E C E C E C E C E C
Gamma nails vs. others
 Adams, 2001 UK N GN SHS 203 197 39/164 49/148 81.2 (8.5) 80.7 (11.7) 111 96 92 101 12
 Ahrengart, 2001 Sweden Y GN SHS 210 216 62/148 61/155 80.5 (NR) 79.0 (NR) 107 144 103 72 6
 Aktselis, 2014 Greece N GN SHS 40 40 12/28 12/28 82.9 (5.8) 83.1 (6.5) 0 0 40 40 12
 Barton, 2010 UK N GN SHS 100 110 19/81 25/85 83.1 (9.5) 83.3 (6.8) 0 0 100 110 12
 Bridle, 1991 UK N GN SHS 49 51 9/40 7/44 82.7 (NR) 81 (NR) 18 23 31 28 6
 Hoffman, 1996 Newzealand N GN SHS 31 36 4/27 12/24 83.2 (8.1) 79.0 (10.4) 21 24 10 12 6
 Kukla, 1997 Austria N GN SHS 60 60 14/46 4/56 83.0 (9.1) 84.0 (8.3) 31 23 29 37 6
 Leung, 1992 HongKong N GN SHS 113 113 25/68 30/63 80.8 (8.4) 78.3 (9.5) 30 20 63 73 12
 O’Brien, 1995 Canada N GN SHS 52 49 9/43 17/32 83.0 (9.5) 77.0 (13.7) 30 28 23 21 12
 Ovesen, 2006 Darmark N GN SHS 73 73 20/53 21/52 79.9 (10) 78.5 (11.7) 23 17 50 56 12
 Park, 1998 Korea N GN SHS 30 30 10/20 14/16 73.7 (NR) 72.2 (NR) 14 11 16 19 18
 Radford, 1993 UK N GN SHS 100 100 79/21 76/24 83 (6.2) 78.0 (5.0) 38 57 62 43 12
 Utrilla, 2004 Spain N GN SHS 104 106 38/66 28/78 80.6 (7.5) 79.8 (7.3) 81 75 23 31 12
 Efstathopoulos, 2007 Greece N GN ACE 56 56 19/37 13/43 79.5 (NR) 78.1 (NR) 12 8 44 48 8
 Grave, 2012 Belgium N GN ACE 61 51 35/26 32/19 73.0 (12.5) 77.0 (14.0) 18 20 43 31 12
 Vidyadhara, 2007 India N GN ACE 37 36 19/18 18/18 68.6 (5.6) 69.4 (4.6) 0 0 37 36 24
 Herrera, 2002 Spain N GN PFN 125 125 71/179 78.9(NR) 13 19 112 98 12
 Schipper, 2004 Netherland Y GN PFN 213 211 37/176 38/173 82.6 (NR) 82.2 (NR) 165 156 48 55 12
 Xu, 2010 (1) China N GN PFNA 70 66 27/43 27/39 75.4 (1.0) 76.0 (1.2) 0 0 70 66 17
 Vaquero, 2012 Spain N GN PFNA 31 33 5/25 3/28 83.5 (7.4) 83.6 (7.5) 0 0 31 33 12
 VarelaEgocheaga, 2009 Spain N GN PCCP 40 40 6/34 11/29 82.5 (NR) 81.6 (NR) 27 24 13 16 12
SHS vs. others
 Janzing, 2001 Netherland N SHS PCCP 44 39 10/34 4/35 83.0 (8.5) 82.0 (7.7) 25 16 19 23 12
 Kosygan, 2002 UK N SHS PCCP 56 55 12/44 9/46 82.8 (9.0) 82.7 (8.5) 25 25 31 30 6
 Peyser, 2007 Israel N SHS PCCP 53 50 18/35 16/34 82.5 (8.0) 78.9 (8.2) 31 29 14 8 12
 Yang, 2011 USA N SHS PCCP 33 33 7/25 11/22 77 (14.2) 76 (17.5) 0 0 33 33 12
 Baumgaertner, 1998 USA N SHS IMHS 68 67 45/86 79 (9.8) 35 31 33 36 28
 Hardy, 1998 Belgium N SHS IMHS 50 50 15/35 8/42 79.5 (10.7) 81.7 (11.8) 16 13 34 37 12
 Harrington, 2002 USA N SHS IMHS 52 50 11/41 9/41 82.1 (8.6) 83.8 (8.5) 0 0 52 50 12
 McCormack, 2013 Canada Y SHS Medoff 86 77 21/65 18/59 83.0 (NR) 83.6 (NR) 0 0 86 77 6
 Watson, 1998 USA N SHS Medoff 91 69 43/117 76 (12.3) 29 17 62 52 16
 Lunsjo, 2001 Sweden Y SHS Medoff 238 268 71/167 67/201 81 (7.8) 81 (9.5) 0 0 238 268 12
 Saudan, 2002 Switzerland N SHS PFN 106 100 22/84 24/76 83.7 (10.1) 83.0 (9.7) NR 12
 Garg,2011 India N SHS PFNA 39 42 27/12 32/10 64.3 (4.5) 60.2 (5.0) 0 0 39 42 40
 Xu, 2010(2) China N SHS PFNA 55 51 16/39 15/36 77.9 (7.8) 78.5 (8.0) 0 0 55 51 12
 Zou, 2009 China N SHS PFNA 63 58 15/48 12/46 65 (13.7) 65 (13.5) 52 42 11 16 12
 Little, 2008 UK N SHS Holland 92 98 8/84 20/78 82.6 (8.0) 84.2 (8.0) 15 29 77 69 12
 Parker, 2012 UK N SHS Targon PF 300 300 52/248 69/231 82.4 (13) 81.4 (12.8) 58 65 242 235 12
PFNA vs. others
 Guo, 2013 China N PFNA PCCP 45 45 16/29 19/26 74.2 (8.8) 71.6 (7.5) 22 18 23 27 12
 Park, 2010 Korea N PFNA PFN 23 17 6/17 3/14 75.7 (6.7) 67.0 (11.0) 7 5 16 12 24
 Tao, 2013 China N PFNA LISS 45 42 16/29 17/25 80.4 (7.3) 79.6 (7.6) 10 9 35 33 12
 Zhou, 2011 China N PFNA LISS 36 28 17/19 13/15 76.2 (15.2) 67.8 (15.7) 8 3 28 25 26
 Wild, 2010 Germany N PFNA Targon PF 40 40 20/20 20/20 81.8 (8.5) 83.1 (11.7) 29 17 62 52 12
Others
 Papasimos, 2005 Greece N GN SHS 40 40 16/24 14/26 82.8 (NR) 81.4 (NR) 0 0 40 40 12
PFN 40 17/23 79.4 (NR) 0 0 40
Table 1.  Characteristics of included studies Y: Yes; N: No; n: number of patients; GN: Gamma Nail; ACE: 
ACE nails; IMHS: Intramedullary Hip Screw; SHS: Sliding Hip Screw; PFN: Proximal Femoral Nail; PFNA: 
Proximal Femoral Nail Antirotation; Medoff: Medoff sliding plate; PCCP: Percutaneous Compression Plate; 
Targon PF: Targon Proximal Femoral; LISS: Less Invasive Stabilization System.
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(SMD: − 0.99, 95%CI − 1.39 to − 0.60, I2 = 66%). SHS had a higher score than IMHS (SMD: 0.43, 95%CI 0.03 to 
0.83), but a lower score than PFNA (SMD: − 0.73, 95%CI − 1.18 to − 0.29) (Table 3). No statistically significant 
differences were presented in other comparisons.
Adverse events. Mortality. Thirty-three trials (n = 5940) reported mortality, all of which were at high risk 
of bias17,18,20–22,24,27–53. The mortality data were collected during the follow up of 6 to 40 months after operations. 
14 trials compared GN versus 4 other implants (SHS, ACE nails, PFN, PCCP); 4 trials compared PFNA versus 3 
other implants (LISS, Tragon PF, PCCP); and 17 trials compared SHS versus 7 other implants (appendix Figs 2–4). 
None of the comparisons showed statistically significant differences, likely due to the very small number of events 
and sample sizes across all the trials (Table 4).
Cut out. Twenty-nine trials (n = 3960)13–19,21–26,28,34–37,41,42,44,46–49,52,54–56 reported cut out data. Of those trials, 5 
reported no event during the course of study (6–40 months)17,26,30,38,57. A total of 141 events were reported from 
3692 patients (3.5%). Eighteen trials reported the comparison of GN versus 5 other implants (SHS, ACE nails, 
PFN, PFNA, PCCP); 11 trials compared SHS versus 6 other implants (appendix Figs 5–7); and 1 trial compared 
PFNA versus Targon PF.
The pooling of the trials showed that GN increased the risk of cut out compared to SHS (43/802 vs. 23/830; 
OR: 1.87, 95%CI 1.08 to 3.21, I2 = 0%). No statistically significant differences were found in other comparisons, 
largely because of the small number of events and sample sizes (Table 4).
Non-union. Data regarding non-union were available in 29 trials (n = 3795), among which 17 reported 90 
non-union events during the follow up (2.37%)17,19,24,26–30,34–42,44,47–54,57–59. Fifteen trials compared GN with other 
Study Intervention Tool
No of pts at 
BL and FU Baseline Mean (SD)
Follow up 
bMean (SD) MD (95%CI)
Aktselis, 2014 GN EuroQol 5D 40/36 0.92 (0.14) 0.90 (0.16) 0.12 (0.02,0.22)
SHS 40/35 0.90 (0.14) 0.78 (0.27)
Barton, 2010 GN EuroQol 5D 100/65 NR 0.46 (NR) —
SHS 110/86 NR 0.37 (NR)
Vaquero, 2012 GN SF-36 28/11 PCS:39.7 (7.9) 35.0 (10.8) PCS:
MCS:51.7 (9.8) 46.3 (12.8) − 1.60 (− 11.54,8.34)
PFNA 27/10 PCS:42.0 (8.1) 36.6 (12.3) MCS:
MCS:46.9 (11.2) 47.8 (11.3) − 1.50 (− 11.81,8.81)
Yang, 2011 PCCP SF-36 33/20 NR 47.50 (NR) —
SHS 33/18 NR 38.60 (NR)
Table 2.  Results of quality of life. GN: Gamma Nail; IMHS: Intramedullary Hip Screw; SHS: Sliding Hip 
Screw; PCCP: Percutaneous Compression Plate; AMBI: AMBI hip screw; PCS: Physical component summary 
score; MCS: Mental component summary score Pts: patients; BL: baseline; FU: follow up; NR: Not reported;  
—: Not applicable.
Intervention N (n) SMD (95%CI) I2 (%)
GN vs.
 SHS 3 (305) 0.23 (0.01,0.46)* 22
 ACE nail 3 (273) − 0.16 (− 0.40,0.08) 61
 PFNA 2 (114) − 0.99 (− 1.39,− 0.60)* 66
SHS vs.
 IMHS 1 (100) 0.43 (0.03,0.82)* —
 PFN 1 (168) 0.06(− 0.24.0.37) —
 PFNA 1 (83) − 0.73 (− 1.18,− 0.29)* —
 Medoff 1 (125) − 0.07 (− 0.42,0.28) —
PFNA vs.
 LISS 2 (151) − 0.01 (− 0.33,0.31) 0
 Targon PF 1 (58) 0.06 (− 0.45,0.58) 0
 PCCP 1 (90) − 0.09 (− 0.50,0.32) —
Table 3. Meta-analysis of functional scores. SMD: standard mean difference; 95% CI: 95% confidence 
interval. GN: Gamma Nail; IMHS: Intramedullary Hip Screw; SHS: Sliding Hip Screw; PFN: Proximal Femoral 
Nail; PFNA: Proximal Femoral Nail Antirotation; PCCP: Percutaneous Compression Plate; Targon PF: Targon 
Proximal Femoral; LISS: Less Invasive Stabilization System. *Statistically significant differences. —:Not 
applicable.
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Intervention
Mortality Cut out Non-union
N (n) Events/total OR (95%CI) I2 N (n) Events/total OR (95%CI) I2 N (n) Events/total OR (95%CI) I2
GN vs.
 SHS 11 (2185) 229/1083 vs. 219/1102 1.08(0.88,1.34) 0% 12 (1632) 43/802 vs. 23/830 1.87 (1.08,3.21)* 0% 11 (1348) 32/566 vs. 27/574 1.21 (0.72,2.06) 0%
 ACE nails 1 (112) 14/61 vs. 12/51 0.97(0.40,2.33) — 1 (73) 1/37 vs. 0/36 3.00 (0.12,76.09) — 1 (85) 0/47 vs. 0/38 — —
 PFN 2 (674) 66/338 vs. 75/336 0.84(0.58,1.22) 0% 2 (508) 18/261 vs. 12/247 1.64 (0.48,5.55) 32% 1 (197) 1/101 vs. 2/96 0.47 (0.04,5.27) —
 PFNA — — — — 2 (154) 0/77 vs. 3/77 0.13 (0.01,2.70) — 2 (154) 2/77 vs. 3/77 0.67 (0.10,4.30) —
 PCCP 1 (80) 1/40 vs. 4/40 0.23(0.02,2.16) — 1 (75) 2/39 vs. 0/36 4.87 (0.23,104.88) — — — — —
SHS vs.
 PCCP 5 (466) 46/242 vs. 29/224 1.53(0.91,2.58) 1% 2 (179) 4/87 vs. 2/92 2.18 (0.39,12.19) 0% 1 (83) 0/44 vs. 0/39 — —
 IMHS 3 (337) 52/170 vs. 46/167 1.15(0.71,1.87) 0% 2 (208) 4/106 vs. 3/102 1.30 (0.28,6.04) 0% 3 (238) 2/121 vs. 2/117 0.96 (0.16,5.67) —
 Medoff 3 (783) 87/384 vs. 77/399 1.25(0.89,1.78) 0% 1 (160) 4/91 vs. 1/69 3.13 (0.34,28.62) — 2 (474) 1/228 vs. 9/246 0.15 (0.03,0.87)* 0%
 PFN 2 (314) 15/160 vs. 20/154 0.68(0.33,1.40) 0% 2 (248) 3/119 vs. 4/129 0.82 (0.15,4.42) 2% 1 (168) 0/89 vs. 0/79 — —
 PFNA 2 (187) 8/94 vs. 8/93 1.0(0.35,2,87) 0% 3 (277) 6/142 vs. 0/135 15.98 (0.87,295.14) — 3 (277) 1/142 vs. 0/135 2.81 (0.11,70.31) —
 Targon PF 1 (600) 81/300 vs. 83/300 0.97(0.68,1.38) — 1 (430) 3/215 vs. 2/215 1.51 (0.25,9.11) — 1 (230) 1/215 vs. 1/215 1.00 (0.06,16.09) —
 Holland 
nail 1 (190) 18/98 vs. 16/92 1.07(0.51,2.25) — — — — — 1 (156) 0/80 vs. 0/76 — —
PFNA vs.
 LISS 2 (164) 6/85 vs. 5/78 1.10(0.32,3.77) 0% — — — — 1 (87) 0/45 vs. 0/42 — —
 Targon PF 1 (80) 9/40 vs. 9/40 1.0(0.35,2.86) — 1 (58) 3/29 vs. 2/29 1.56 (0.24, 10.09) — 1 (58) 0/29 vs. 1/29 0.32 (0.01,8.24) —
 PCCP 1 (61) 0/30 vs. 0/31 Not estimable — — — — — — — — —
Intervention
Re-operation Intra-operative fracture Later fracture
N (n) events/total OR(95%CI) I2 N (n) events/total OR (95%CI) I2 N (n) events/total OR (95%CI) I2
GN vs.
 SHS 13 (1846) 53/907 vs. 35/939 1.61(1.02,2.53)* 0% 11 (1722) 22/861 vs. 5/861 3.14 (1.34,7.35)* 0% 12 (1407) 18/703 vs. 2/704 3.67 (1.37,9.83)* 0%
 PFN 2 (511) 30/261 vs. 35/250 0.86(0.40,1.84) 40% 1 (250) 19/125 vs. 5/125 4.30 (1.55,11.92)* 2 (511) 5/261 vs. 4/250 1.27 (0.03,46.52) 74%
 PFNA 1 (93) 0/47 vs. 1/46 0.32(0.01,8.04) — — — — — 2 (154) 2/77 vs. 3/77 0.75 (0.08,6.83) 24%
SHS vs.
 PCCP 3 (261) 13/131 vs. 7/130 1.69(0.32,8.96) 61% — — — — 1 (83) 0/44 vs. 0/39 — —
 IMHS 1 (70) 4/35 vs. 3/35 1.38(0.28,6.66) — 3 (337) 0/170 vs. 6/167 0.20 (0.03,1.17) 0% 2 (168) 0/86 vs. 0/82 — —
 Medoff 2 (474) 8/228 vs. 11/246 1.25(0.24,6.39) 63% — — — — — — — —
 PFN 2 (248) 5/129 vs. 11/119 0.76(0.10,5.62) 64% 2 (286) 0/146 vs. 0/140 — — 2 (247) 0/128vs. 1/119 0.33 (0.01,8.22) —
 PFNA 3 (300) 10/154 vs. 2/146 3.21(0.34,30.55) 50% 1 (106) 0/55 vs. 2/51 0.18 (0.01,3.81) — 2 (204) 0/106 vs. 1/98 0.30 (0.01,7.65) —
 Targon PF 1 (430) 9/215 vs. 3/215 3.09(0.82,11.56) — — — — — 1 (430) 0/215 vs. 1/215 0.33 (0.01,8.19) —
 Holland 
nail 1 (156) 1/80 vs. 0/76 2.89(0.12,71.96) — — — — — 1 (156) 0/80 vs. 0/76 — —
PFNA vs.
 PFN 1 (40) 0/17 vs. 1/23 0.43(0.02,11.18) — — — — — 1 (40) 0/17 vs. 1/23 0.43 (0.02,11.18) —
 LISS 1 (59) 1/34 vs. 2/25 0.35(0.03,4.07) — — — — — — — — —
 Targon PF 1 (58) 4/29 vs. 2/29 2.16(0.36,12.84) — — — — — 1 (58) 1/29 vs. 0/29 3.11 (0.12,79.43) —
Intervention
Wound infection Embolism
N (n) events/total OR(95%CI) I2 N (n) events/total OR (95%CI) I2
GN vs.
 SHS 11 (1433) 20/710 vs. 22/723 0.94(0.49,1.79) 0% 7 (886) 27/440 vs. 24/446 1.08 (0.61,1.92) 0%
 ACE nails 3 (246) 3/125 vs. 4/121 0.85(0.18,4.04) — 2 (173) 1/88 vs. 0/85 3.52 (0.14,88.76) —
 PFN 2 (511) 25/261 vs. 17/250 1.46(0.76,2.79) 0% 2 (511) 2/261 vs. 6/250 0.32 (0.06,1.64) 0%
 PFNA 2 (197) 1/100 vs. 5/97 0.28(0.04,1.87) 0% — — — —
SHS vs.
 PCCP 2 ((179) 2/87 vs. 0/92 3.25(0.33,31.88) 0% 2 (179) 11/87 vs. 4/92 3.40 (1.02,11.26)* 0%
 IMHS 1 ((70) 0/35 vs. 0/35 — — 1 (70) 3/35 vs. 1/35 3.19 (0.32,32.24) —
 Medoff 2 (474) 5/228 vs. 2/246 2.41(0.53,10.90) 0% 1 (349) 1/165 vs. 0/184 3.36 (0.14,83.17) —
 PFN 2 (248) 2/129 vs. 4/119 0.47(0.08,2.78) — 2 (248) 6/129 vs. 4/119 1.44 (0.39,5.37) 0%
 PFNA 2 (204) 4/106 vs. 2/98 1.83(0.31,10.84) 0% — — — —
 Targon PF 1 (430) 4/215 vs. 4/215 1.00(0.25,4.05) — — — — —
 Holland 
nail 1 (156) 10/80 vs. 5/76 2.03(0.66,6.24) — 1 (156) 1/80 vs. 0/76 2.89 (0.12,71.96) —
PFNA vs.
 LISS 1 (59) 0/34 vs. 0/25 — — 1 (87) 1/45 vs. 0/42 2.87 (0.11,72.29)
 Targon PF 1 (58) 4/29 vs. 2/29 2.16(0.36,12.84) — — — — —
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4 implants (SHS, ACE nails, PFN, PFNA); 12 tested the effect of SHS and other 7 devices; 2 compared PFNA with 
LISS and Targon PF (appendix Figs 8–10).
The pooling analysis suggested that SHS was associated with a lower risk of non-union compared to IMHS 
(1/228 vs. 9/246; OR: 0.15, 95%CI 0.03 to 0.87, I2 = 0%), but did not found statistically significant differences in 
other comparisons, again mostly because of the small number of events and sample sizes (Table 4).
Re-operation. Thirty-one trials (n = 4506) reported re-operation. A total of 248 re-operation events occurred in 
4506 participants (5.5%)17,18,21,22,26,27,29,30,32–42,44–46,48–51,53,54,56,57,59. Sixteen trials compared GN with other 3 implants 
(SHS, PFN, PFNA); 14 compared SHS with other 7 implants; and 3 compared PFNA with PFN, LISS and Targon 
PF, respectively (appendix Figs 11–13).
Most of comparisons were made with few trials. The pooling of trials showed that GN increased the risk of 
re-operation compared to SHS (53/907 vs. 35/939; OR: 1.61, 95%CI 1.02 to 2.53, I2 = 0%) (Table 4). No statistically 
significant differences were found between the other comparisons.
Intra-operative fracture. A total of 17 trials (n = 2661) reported intra-operative fracture data17,21,22,27,29,30,34,36–42, 
47,49,54. Of those, 59 intra-operative fractures occurred during the follow up (2.21%). Five comparisons were made 
among those trials, including the comparisons between GN versus SHS, GN versus PFN, SHS versus IMHS, SHS 
versus PFN, and SHS versus PFNA (appendix Figs 14,15).
Most of the comparisons did not demonstrated statistically significant differences because of the small number 
of events. However, the pooling of the trials showed increased risk of intra-operative fracture in patients receiving 
GN versus those with SHS (22/861 vs. 5/861; OR: 3.14, 95%CI 1.34 to 7.35, I2 = 0%), and in patients with GN versus 
with PFN (19/125 vs. 5/125; OR: 4.30, 95%CI 1.55 to 11.92) (Table 4).
Later fracture. Twenty-six trials, totaling 3508 patients and 42 events, reported data on later fracture 
rate17,19,21,22,26,29,30,33,34,36–42,44,47,50,51,53,54,56–59. Sixteen trials compared GN with other 3 implants; 9 compared SHS 
with other 6 devices; 1 compared PFNA with PFN; and the other 1 compared PFNA with Targon PF (appendix 
Figs 16–18).
Again, most of the comparisons did not show statistically significant differences between the alternative surgical 
options. Pooling of the trials comparing GN versus SHS, however, showed that GN was associated with increased 
risk of later fractures (18/703 vs. 2/704; OR 3.67, 95%CI 1.37 to 9.83, I2 = 0%) (Table 4).
Wound infection. Thirty trials reported wound infections (superficial infections and deep infections) 
(n = 4265)18,19,21–27,29,30,32–34,36,38–42,45,46,48,50,51,53,54,57–59. Among those, a total of 147 patients (3.4%) reported to have 
wound infection events. Eighteen trials compared GN with other 4 implants (SHS, ACE nails, PFN, PFNA); 11 
compared SHS with 7 devices; and 2 compared PFNA with LISS and Targon PF (appendix Figs 19–21). None of 
the comparisons showed statistically significant differences in the risk of wound infection (Table 4).
Embolism. A total of 21 trials (n = 2655) provided data on embolism (deep venous embolism and pulmonary 
embolism), and 88 embolic events occurred in 2657 participants (3.3%)21–24,27,29,31,33,36,37,41,42,45,46,48,50,54,59. Eleven 
trials reported the comparative outcomes of GN and 3 other implants, 7 trials tested the effect of SHS and other 
5 devices; and one trial compared PFNA with Targon PF (appendix Figs 22–24). Of 9 comparative groups, SHS 
increased the risk of embolism compared to PCCP (11/87 vs. 4/92; OR: 3.40, 95%CI 1.02 to 11.26, I2 = 0%) 
(Table 4).
Procedure measures. Operative time (min). Differences between internal fixation treatments on operation 
duration were reported in 34 trials including 5692 patients[17–19,22–26,29,30,32,34–36,38–42,46–53,55–59. Heterogeneity across 
the studies were high in some comparisons. 15 trials compared GN with other 4 implants (SHS, ACE nails, PFN, 
PFNA); 16 trials compared SHS with 7 other devices; and 3 trials compared PFNA with 3 implants (appendix Figs 
25–27). We found a substantial difference on operative time among varied comparisons, likely due to different 
definitions in original trials. Overall, PFNA were associated with less operative time than other internal fixation 
treatments (PFNA vs. GN: (MD:− 4.45, 95%CI − 5.17 to − 3.73, I2 = 0%); PFNA vs. LISS: (MD: − 26.78, 95%CI 
− 32.8 to − 20.75, I2 = 0%); PFNA vs. Targon PF: (MD: − 18.5, 95%CI − 30.63 to − 6.37); PFNA vs. PCCP: (MD:13.5, 
95%CI 7.54 to19.46)) (Table 5).
Blood loss (mL). Data on blood loss were available in 19 trials (n = 3475)20,21,25–27,30–33,35,39,46–48,50,52,54,55,57. 
Heterogeneity across the studies were high in some comparisons. 7 trials compared GN with other 4 implants 
(SHS, ACE nails, PFN, PFNA); 9 trials compared SHS with 5 other devices; and 3 trials compared PFNA with LISS 
and PCCP (appendix Figs 28–30). Overall, patients who underwent SHS had more blood loss than those who 
were treated with other internal fixation implants (SHS vs. IMHS: (MD: 62.42, 95%CI 26.28 to 98.56, I2 = 0%); 
SHS vs. PFNA: (MD: 253.86, 95%CI 237.47 to 270.25, I2 = 0%); SHS vs. Holland nail: (MD: 82.0, 95%CI 37.81 to 
126.91) (Table 5).
Table 4.  Meta-analysis of adverse events. N: the number of studies; n: number of patients. GN: Gamma Nail; 
IMHS: Intramedullary Hip Screw; SHS: Sliding Hip Screw; PFN: Proximal Femoral Nail; PFNA: Proximal 
Femoral Nail Antirotation; PCCP: Percutaneous Compression Plate; Targon PF: Targon Proximal Femoral; 
LISS: Less Invasive Stabilization System. *Statistic significant difference; —: Not appliance.
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Hospital stay (days). A total of 22 trials (n = 3705) reported the duration of hospital stay18,19,26,29–35,37–40,43,45–
48,51,52,54. 11 trials compared GN with other 4 implants (SHS, ACE nails, PFN, PCCP); 9 trials compared SHS with 6 
other devices; and 3 trials compared PFNA with LISS and PCCP (appendix Figs 31–33). One comparison revealed 
that PFN had longer hospital stay compared to GN (MD: 2.7, 95%CI 2.44 to 2.96), and no significant differences 
were found in other 11 comparisons of devices (Table 5).
Sensitivity analysis. The sensitivity analyses using alternative analysis methods (Peto method vs. 
Mantel-Haenszel method), and considerations of heterogeneity (random-effects vs. fixed-effect) did not show 
important changes in the pooled effects for these outcomes.
Discussion
Our study has identified a wide variety of internal fixation implants for patients with intertrochanteric fracture, 
among which sliding hip screw (SHS) and gamma nail (GN) were the most commonly investigated treatment 
options, as evident from the trials. The other implants, including percutaneous compression plate (PCCP), proximal 
femoral nail antirotation (PFNA), and proximal femoral nail (PFN), also are often investigated.
The findings from those trials suggested that substantial uncertainty regarding the relative effects – both benefits 
and harms – remain among those alternative internal fixation strategies, except only a few comparisons, because of 
the small number of sample sizes with the vast majority of trials and the serious limitations that threat the validity 
(e.g. failure to conceal treatment allocation).
The quality of life and functional status are of important interest to surgical treatment and are often used in 
orthopedics surgical trials60–64. However, our review identified under-reporting of these outcomes. In the trials 
having reported these two outcomes, the completeness of data remains less satisfied in most circumstances – many 
trials failed to report the baseline data and the change from baseline; even if reported, the standard deviations 
were not available. All those limitations have made fair comparison of alternative internal fixation strategies less 
likely. Given the current body of evidence, it is uncertain if the quality of life would be improved after the surgical 
interventions, and which of surgical treatment would achieve better quality of life. In our analyses of the func-
tional scores, the findings similarly suggested a lack of evidence, and no definitive conclusions can be made for 
most of the comparisons. However, it seems from the analyses that patients receiving PFNA might achieve better 
functional status after surgery than those receiving GN or SHS. This finding was preliminary given the limitations 
of the included trials.
The trials extensively reported complications of internal fixation treatments. However, due to the small sample 
sizes and methodological limitations, the current body of evidence is inadequate to draw clear conclusion for most 
of the comparisons. The analyses suggested substantial uncertainty of relative effects on complications between 
internal fixation strategies. However, a number of trials compared GN and SHS. The analyses consistently suggested 
that patients receiving GN may have significantly higher risk of complications than those SHS, including the risk 
of cut out, operations, intra-operative fracture, and later facture. The consistency of findings across studies and 
outcomes, and the relatively large magnitude of effect increases the credibility of this finding. A few other studies 
also suggested that SHS might have a lower risk of non-union, but have a higher risk of embolism than PCCP. 
Intervention
Operative time (min) Blood loss (mL) Hospital stay (day)
N (n) MD (95%CI) I2 N (n) MD (95%CI) I2 N (n) MD (95%CI) I2
GN vs. 
 SHS 10 (1817) − 0.49 (− 7.40,6.41) 94% 4 (1114) − 21.41 (− 97.2,54.37) 79% 7 (909) 0.64 (− 1.61,1.15) 0%
 ACE nails 2 (185) − 7.16 (− 14.99,0.68) 85% 1 (73) − 13.0 (− 19.22,− 6.78)* — — — —
 PFN 1 (424) 0.0 (− 0.38,0.38) — 1 (424) 67.0 (64.01,69.99)* — 1 (374) − 2.7 (− 2.96,− 2.44)* —
 PFNA 2 (197) 4.45 (3.73,5.17)* 0% 1 (136) 55.3 (50.53,60.07)* — 2 (197) 0.20 (0.13,0.27) 0%
 PCCP — — — — — — 1 (118) − 0.1 (− 0.52,0.32) —
SHS vs.
 PCCP 4 (360) 7.89 (− 8.16,23.95) 92% 2 (169) 133.04 (− 16.74,282.83) 93% 2 (211) − 0.32 (− 2.43,1.78) 0%
 IMHS 3 (342) − 8.83 (− 25.06,7.39) 85% 2 (235) 62.42 (26.28,98.56)* 0% 2 (237) − 1.00 (− 3.37,1.37) 0%
 Medoff 2 (666) − 29.50 (− 58.89,− 0.12)* 95% 2 (666) − 99.05 (− 166,− 32.1)* 69% 1 (506) 0.00 (− 1.33,1.33) —
 PFN 2 (286) 2.30 (− 5.04,9.64) 0% — — — 2 (314) − 0.07 (− 1.68,1.54) 0%
 PFNA 3 (308) 14.0 (− 16.50,44.50) 99% 2 (227) 253.86 (237.47,270.25)* 0% 1 (106) 0.40 (− 0.23,1.03) —
 Targon PF 1 (600) − 3.0 (− 5.0,− 1.0)* — — — — 1 (600) − 2.5 (− 10.61,5.61) —
 Holland nail 1 (190) − 13.7 (− 19.25,− 8.15)* — 1 (190) 82.0 (37.81,126.91)* — — — —
PFNA vs.
 LISS 2 (151) − 26.78 (− 32.8,− 20.75)* 0% 2 (151) − 25.11 (− 62.59,12.07) 0% 2 (151) 0.51 (− 3.99,5.01) < 0.001
 Targon PF 1 (80) − 18.5 (− 30.63,− 6.37)* — — — — — — —
 PCCP 1 (90) 13.5 (7.54,19.46)* — 1 (90) 37.5 (20.88,54.12) — 1 (90) 0.8 (− 0.84,2.44) —
Table 5.  Meta-analysis of procedure measure N: the number of studies; n: number of patients. GN: Gamma 
Nail; IMHS: Intramedullary Hip Screw; SHS: Sliding Hip Screw; PFN: Proximal Femoral Nail; PFNA: Proximal 
Femoral Nail Antirotation; PCCP: Percutaneous Compression Plate; Targon PF: Targon Proximal Femoral; 
LISS: Less Invasive Stabilization System. *Statistically significant difference.
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These findings were, however, fragile given the small number of events and sample sizes, as well as the potential 
risk of bias those studies pose.
A number of trials also reported procedure measures (operation time, blood loss, and hospital stay). The find-
ings were however inconsistent across studies, which resulted in substantial heterogeneity. The presence of the 
varying procedural outcomes across studies may represent the differential levels of expertise among the surgeons 
participating in those trials. Overall, the results suggested patients undergoing PFNA may have shorter operative 
time, and patients undergoing SHS may have more blood loss than other extramural implants.
Compared to the Cochrane systematic review that compared intramedullary nails with SHS for extracapsular 
hip fractures14, we excluded subtrochanteric fractures and assessed more extramedullary implants. The Cochrane 
Review conducted in 2010 included 43 RCTs that set no limit regarding the length of follow up. They found that the 
SHS was a better fixation device for the intertrochanteric fractures than nails. They also suggested intramedullary 
nails have advantages over extramedullary plates/screws for some unstable intertrochanteric fractures. Considering 
a wide variety of implants with inconsistent outcomes and low precision of estimate effects, we suggest that cautions 
need to be taken in drawing any definite conclusions.
We conducted a comprehensive systematic review using rigorous methods. However, there are a few limitations. 
First, because of the limited availability of data, we compared means of functional scores at the end of follow up 
between treatment groups. We assumed that the data at baseline were well balanced between groups. However, 
this assumption may not always be hold. Second, the trials we included in the analysis suffered from important 
methodological limitations, as many other surgical trials. The potential risk of bias that those trials poses has 
weakened our inference of the treatment effects. Third, most of the trials included in our analyses were small in 
sample sizes. This has resulted in imprecise estimation of effects, and definitive conclusion is unlikely for most of the 
comparisons. Fourth, due to the limited evidence with different types of fractures (69.7% of studies did not take into 
account of the fracture stability), we were unable to explore if the treatment effects might differ by fracture types.
In conclusion, due to the small number of events and sample sizes and serious limitations that those trials pose, 
the current body of evidence is inadequate to establish the relative effects – including quality of life, functional 
scores, and complications – of all of the alternative internal fixation strategies. However, the evidence suggests 
that patients undergoing GN may have a higher risk of complications than those receiving SHS. Future trials that 
are adequately powered and well designed and conducted are warranted to fairly test the effects of the different 
surgical treatments. Observational studies that are carefully collect and analyze the data may also provide important 
insights regarding the effects of the surgical treatments.
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